Zobrazeno 1 - 10
of 66
pro vyhledávání: '"E. Longeval"'
Autor:
J. Klastersky, A. Ferrant, E. Longeval, A. Hendrikx, J.M. Lachapelle, K.J. Van Acker, E. Schoffeniels
Publikováno v:
Acta clinica Belgica. 33(1)
Publikováno v:
Revue medicale de Bruxelles. 11(3)
A 76 year-old man with urothelial carcinoma of the bladder presented marked leucocytosis (69,300 mm3) and hypercalcemia (15.4 mg/mm3). The paraneoplastic origin of these observations was demonstrated. The authors review other reported cases and discu
Autor:
Jean Klastersky, Otilia Dalesio, E. Longeval, J. Michel, D. Becquart, G Vandermoten, P. Rocmans, J.P. Dumont, Jean-Paul Sculier
Publikováno v:
Cancer. 56:71-75
The current study reports the results of Adriamycin (doxorubicin), etoposide, and cyclophosphamide (AVE) in small cell bronchogenic carcinoma. The overall rate of response was 82% in patients with limited disease and 66% in patients with extensive di
Autor:
E. Longeval, Marc L'Hermite, E. Van Cauter, Abraham Borkowski, Carl Muquardt, M. Rozencweig, Pierre Dor
Publikováno v:
Journal of Endocrinology. 73:235-246
The endocrine response to prolonged dexamethasone treatment was investigated in six postmenopausal women with generalized mammary carcinoma. Plasma cortisol levels decreased rapidly and became undetectable whereas significant concentrations of plasma
Autor:
H. Bondue, Nadine Crespeigne, J. Lardinois, Michel Clavel, Marcel Rozencweig, Harry Bleiberg, Yvon Kenis, J. Michel, E. Longeval, W. Feremans
Publikováno v:
European Journal of Cancer and Clinical Oncology. 17:863-866
The single agent activity of chlorozotocin was evaluated in advanced colorectal cancer not previously treated with chemotherapy. The drug was given at a dosage of 200 mg/m 2 i.v. repeated every 6 wk . Of 23 evaluable patients, 2 achieved a partial re
Autor:
Otilia Dalesio, P. Van Houtte, E. Longeval, Pol Ravez, J. Michel, Jean-Paul Sculier, Jean Klastersky, P. Mommen, G Vandermoten, D. Becquart, M Mairesse, P. Libert, P. Rocmans, A. Flemalle, Jacques Thiriaux
Publikováno v:
European Journal of Cancer and Clinical Oncology. 24:519-526
One hundred and twelve patients with small cell lung cancer (SCLC) were treated with a combination (CAVE) of cisplatin ( 60 mg/m 2 day 1), adriamycin ( 45 mg/m 2 day 1), etoposide ( 80 mg/m 2 days 1-2-3) and cyclophosphamide ( 1 g/m 2 day 1) given ev
Publikováno v:
Cancer. 50:652-658
Chemotherapy with a combination of cisplatin (60 mg/m2), Adriamycin (45 mg/m2), and etoposide (120 mg/m2 X 3) (CAV) has been evaluated in 36 patients with small-cell bronchogenic carcinoma (SCBC) after two full courses. The complete response (CR) rat
Autor:
E. Longeval, Richard Sylvester, Marie Christine Deboel, Wolrad Mattheiem, Guy Leclercq, Jean-Claude Heuson
Publikováno v:
Cancer. 39:1971-1977
The predictive significance of quantitative assessment of estrogen receptors in tumor tissue was analyzed in women with advanced breast carcinoma. Receptor concentration was measured by the 3H-estradiol binding capacity of the cytosol fraction of bio
Autor:
C, Focan, A, Baudoux, M, Beauduin, U, Bunescu, N, Dehasque, L, Dewasch, J P, Lobelle, E, Longeval, F, Majois, E, Salamon
Publikováno v:
Anticancer research. 6(5)
In a prospective randomized trial comparing CMF to CMF + HD-MPA for primary node positive breast cancer patients, the authors evidenced clear improvement of hematological tolerance (especially of WBC - granulocytes counts) to chemotherapy in the grou
Publikováno v:
Cancer treatment reports. 64(12)
A phase II clinical trial of high-dose cisplatin (120 mg/m2 iv every 3 weeks), with fluid and mannitol-induced diuresis, was conducted in 81 patients with advanced lung cancer. Partial remissions were documented in 26% of 75 evaluable cases for a med